Myelodysplastic syndromes (MDS) are malignant clonal disorders of haematopoietic stem
cells and their microenvironment, affecting older individuals (median age∼ 70 years) …

Glossary: CFU-E, erythroid colony forming unit; CFU-S, spleen colony forming unit; BFU-E,
erythroid burst forming unit; CFU-GM, granulocyte-macrophage colony forming unit; TNF-α …

Background: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic
stem-cell disorder in which the affected cells are deficient in glycosylphosphatidylinositol …

Thalidomide was administered to 83 patients with myelodysplastic syndrome (MDS), starting
at 100 mg by mouth daily and increasing to 400 mg as tolerated. Thirty-two patients stopped …

Apoptosis of haemopoietic cells in the marrow of patients with myelodysplastic syndrome
(MDS) has been suggested as a mechanism for peripheral cytopenias. We determined the …

BACKGROUND. Tumor necrosis factor (TNF)‐α and other cytokines are involved in the
pathogenesis of acute myeloid leukemia (AML) and high‐risk myelodysplastic syndromes …

The myelodysplastic syndrome (MDS) includes a diverse group of clonal and potentially
malignant bone marrow disorders characterized by ineffective and inadequate …

The mechanism that leads to hemopoietic failure in patients with myelodysplastic syndrome
(MDS) is not well understood. There is evidence, however, that regulatory molecules such …

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL), a member of the tumor
necrosis factor (TNF) family, binds to several cell-surface receptors with distinct functions …

Background Allogeneic stem cell transplantation is usually considered the only curative
treatment option for patients with advanced or transformed myelodysplastic syndromes in …